

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

BIOHARVEST SCIENCES INC.
Suite 1140 – 625 Howe Street
Vancouver, BC, V6C 2T6

Item 2. Date of Material Change

June 10, 2020

Item 3. News Release

The news release was issued on June 10, 2020 and was disseminated by Stockwatch.

Item 4. Summary of Material Change

BioHarvest Sciences Inc. (the “Company”) announced the appointment of Mr. Eitan Popper as the Chairman of the Company’s Board of Advisors.

Item 5. Full Description of Material Change

BioHarvest Sciences Inc. (CSE: BHSC)

The Company announced the appointment of Mr. Eitan Popper as the Chairman of the Company’s Board of Advisors. Mr. Popper will assist the Company’s senior management team with strategic matters, including but not limited to outlining the Company’s Cannabis related strategy and the development of key strategic partnerships within the Cannabis industry.

Under the terms of Mr. Poppers appointment, the Company will grant him a total of 10,858,917 incentive stock options. The options will be exercisable at a price of \$0.15 per share for a 10- year period, vesting quarterly over a 2-year period.

Item 6. Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

None.

Item 8. Executive Officer

Zaki Rakib
CEO
604-622-1186

Item 9. Date of Report

June 16, 2020



BIOHARVEST SCIENCES INC.

June 10, 2020

CSE Symbol: BHSC

BioHarvest Sciences Inc. Appoints Eitan Popper as Chairman of the Advisory Board

Vancouver, BC / June 10, 2020 / BioHarvest Sciences Inc. (the “Company”) (CSE: BHSC) BioHarvest Sciences Inc. (BHSC) is announcing today the appointment of Mr. Eitan Popper as the Chairman of the Company's Board of Advisors. Mr. Popper will assist the Company's senior management team with strategic matters, including but not limited to outlining the Company's Cannabis related strategy and the development of key strategic partnerships within the Cannabis industry.

Mr. Popper was the co-founder and President of MedReleaf Corp., which was acquired in 2018 for 2.5B USD, in what is considered the largest Cannabis industry exit to date. Prior to its acquisition, MedReleaf was one of the largest and most reputable vertically integrated medical Cannabis producers in the world. Mr. Popper brings over 15 years of international partnerships, entrepreneurial ventures, disruptive industry, large scale project management, engineering and investment experience. Mr. Popper holds a B.Sc. in civil engineering from the UIA in Mexico, an M.Sc. in Environmental Fluid Mechanics from Stanford University, and an MBA from the Recanati School of Business at Tel Aviv University.

“Mr. Popper brings invaluable experience that will help the Company implement its biofarming technology within the Cannabis industry” said Dr. Zaki Rakib, Chairman of the Board of Directors, and added “His successful track record along with his extensive industry network will not only set the right Cannabis strategy but ensure the best way of execute such strategy. Cooperating with existing successful players in the industry will accelerate the adoption of the Company's technology, which is set to change Cannabis production as we know it. In his role as Chairman of the Board of Advisors, Mr. Popper will also be identifying and incorporating additional advisors who will further support the company's growth. On behalf of the Board of Directors and the Company's management, I would like to welcome Eitan and, I am looking forward along with the new CEO (Mr. Ilan Sobel) to take advantage of his knowledge and capabilities”.

“I'm very happy to join BHSC's talented team and I'm looking forward to support the Company, as it further scales its unique plant cell technology platform. I was fortunate to meet the BHSC team over a year ago, and since then have visited the Company's GMP and ISO certified facilities multiple times. I was very impressed when I learned about the Company's proprietary technology, as it allows to produce any herbal API and full spectrum plant-based products, at industrial scale, under GMP conditions, and - at a fraction of the price when compared to conventional farming and extraction. It is important to note that BHSC's provides access to natural plant-based compounds without the use of pesticides during cultivation or the need of solvents for extraction. Lastly, I was even more impressed when I learned about BHSC's more recent ground-breaking achievements, specifically with Cannabis cells. Including successfully growing cannabis cells and trichomes in small scale bioreactors, and successfully producing six distinct cannabinoid molecules, at lab scale”, said Mr. Eitan Popper, co-founder of MedReleaf and now Chairman of the Board of Advisor at BioHarvest Sciences Inc.

Click on the following hyperlink for a visual description of our Biofarming Technology: [BHSC's Biofarming Technology](#)



Under the terms of Mr. Poppers appointment, the Company will grant him a total of 10,858,917 incentive stock options. The options will be exercisable at a price of \$0.15 per share for a 10- year period, vesting quarterly over a 2-year period.

About BioHarvest Sciences Inc.

Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent protected Biofarming technology. It is the first and only industrial large-scale plant cell growth technology capable of directly and constantly producing the active plant ingredients without the necessity to grow the plant itself. The technology has been already validated by Vinia, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest. By adapting this technology to the Cannabis plant, and building adequate cells production capacity, BioHarvest Sciences Inc.'s objective is to become the leading supplier of Cannabis for both the medicinal and recreational legal use. See the following hyperlink for a visual description of our Biofarming technology: [BHSC's Biofarming Technology](#)

BioHarvest Sciences Inc.

Dr. Zaki Rakib
President and Chairman of the Board

For further information, please

contact: Dave Ryan, VP Investor
Relations & Director Phone: 1 (604) 622-
1186
Email: dave@bioharvest.com

Forward-Looking Statements Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Neither Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release

